Grace Halsey

Managing post–MI distress is no longer optional—it’s essential to comprehensive cardiac recovery, according to a new AHA statement.

The sBLA includes data from the phase 3 INHALE-1 study, which showed Afrezza noninferior to MDI insulin. A PDUFA date is set for May 29, 2026.

Based on the PREVENT algorithm's estimates of 10-year ASCVD risk, 4.2 million adults may need to be reevaluated for aspirin discontinuation, authors reported.

Roche's Elecsys pTau181 test has a 97.9% negative predictive value to rule out amyloid pathology, which will improve referral decisions and expedite treatment.

Anderson and Vega discuss CGM use in primary care, obesity management, immunization challenges, and cognitive decline in older adults.

New global WHO data show escalating resistance in key bacterial pathogens, threatening frontline antibiotics and narrowing treatment options worldwide.

Vega considers the impact of recent changes in immunization policy on trust not just among patients but among clinicians as well. It all threatens good patient care, he said.

Telemedicine follow-up after hospital discharge for COPD exacerbation was significantly more effective than standard care and received high patient satisfaction scores.

Clinical and real-world data are on deck for lumateperone, seltorexant, and esketamine to treat major depressive disorder and treatment-resistant depression.

OLPs did not affect migraine frequency but did subjectively improve QoL, with authors noting they may have a role as a supportive treatment option for select patients.

Time in range, glucose variability, and postprandial spikes: Anderson highlights how CGM insights translate quickly into targeted treatment decisions.

Approval of the novel oral PDE4B inhibitor offers hope to individuals with the rare, chronic, and progressive pulmonary disease for which treatment options are few.

The Frist Clinic clinician said that technical difficulty is not impeding CGM uptake in primary care. "The real limitation is they just haven't done it before."

Post-Dobbs data reveal medication abortion now represents nearly two-thirds of all US abortions. Wetterer reviews trends and implications.

As dementia care grows more complex and more promising, the role for front-line clinicians is becoming more nuanced and more essential.

AstraZeneca will share the positive topline 24-hour BP monitoring data with global regulatory authorities and present findings at the 2025 AHA Scientific Sessions.

John E Anderson, MD, discusses why primary care lags in CGM adoption despite proven benefits, stressing that it's largely a lack of familiarity and that's easily overcome.

Psoriasis, lichen planus, and pityriasis rosea share overlapping presentations and comorbidities, but distinct pathophysiologies require accurate diagnosis and tailored therapeutic approaches.

The approval of roflumilast 0.05% provides a steroid-free, once-daily treatment option for safe and effective long-term management of pediatric eczema.

Barriers to increasing guideline-recommended CRC screening rates are slow to fall, but ongong focused counseling and advocacy in primary care will support the progress.

Semaglutide and tirzepatide "should be first-line treatment" for people with obesity and its myriad of complications, says EU obesity professional association.

The ReCODE program targets metabolic, infectious, immune, vascular, and toxic exposures, elements that underlie both mood and cognition, study authors said.

FDA did not announce the September 30 approval, which took place despite strong partisan opposition and during an uncompleted review of the drug's safety.

Moore describes the ACIP's shared decision making approach to COVID-19 vaccination as a "passive recommendation" that will surely exclude at-risk US populations.

The premonitory constellation of neurologic, autonomic, and behavioral symptoms is increasingly understood as the earliest manifestation of migraine pathophysiology.

Linus Health will demonstrate advances in remote assessment platforms and digital biomarkers of cognitive health that can bring precision medicine to primary care.

Remibrutinib is the first oral BTK inhibitor for chronic spontaneous urticaria, with a dual mechanism of action that blocks 2 key autoimmune mechanisms.

Lipocene expects to announce interim safety data from the study this quarter and said the phase 3 program results will support the company's NDA in 2026.

The binational cohort study of exposure to 4 traditional CVD risk factors over time revealed that 99% of CVD events were preceded by suboptimal levels of at least one.

Vertanical's VER-01 shows promise in reducing chronic low back pain, outperforming opioids and maintaining relief for over a year.